CD276 and colorectal carcinoma: By analyzing the CD276 mRNA expression and clinical outcome results from The Cancer Genome Atlas (TCGA) (stage I-IV, n = 597, Fig. 1G) 33, we found that CRC patients with low CD276 mRNA had favorable survival outcomes (log-rank p=0.008, HR=1.606, 95% CI=1.103-2.339), which was consistent with our results.